We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+30.91%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$667M
AUM Growth
+$297M
Cap. Flow
+$192M
Cap. Flow %
28.79%
Top 10 Hldgs %
91.1%
Holding
20
New
4
Increased
–
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
KRON
Kronos Bio
KRON
+$120M
2
SPRB
Spruce Biosciences
SPRB
+$47.8M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$27.3M
4
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$14.3M

Top Sells

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$11.3M
2
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$1.91M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$1.66M
4
EPIX
ESSA Pharma
EPIX
+$1.46M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$458K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$814M
$194M 29.03%
5,074,783
-270,188
-5% -$11.3M
KRON
2
DELISTED
Kronos Bio
KRON
$114M 17.1%
+3,818,283
New +$120M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$98M 14.7%
2,921,771
-56,061
-2% -$1.66M
SPRB
4
Spruce Biosciences
SPRB
$119M
$52.5M 7.88%
+28,814
New +$47.8M
AVIR icon
5
Atea Pharmaceuticals
AVIR
$379M
$35.4M 5.31%
+847,208
New +$27.3M
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$32.1M 4.82%
3,320,608
– –
IMUX icon
7
Immunic
IMUX
$182M
$27.3M 4.1%
178,816
– –
CMPI
8
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$19.5M 2.92%
1,335,050
– –
ARQT icon
9
Arcutis Biotherapeutics
ARQT
$3.42B
$18M 2.7%
640,199
-18,709
-3% -$458K
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$17M 2.54%
+156,250
New +$14.3M
PRTK
11
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$16.3M 2.44%
2,600,410
– –
ALPN
12
DELISTED
Alpine Immune Sciences Inc
ALPN
$16.2M 2.43%
1,284,900
– –
EPIX
13
DELISTED
ESSA Pharma
EPIX
$8.42M 1.26%
705,693
-207,000
-23% -$1.46M
KYNB
14
Kyntra Bio
KYNB
$28.5M
$4.85M 0.73%
5,226
– –
CDTX
15
DELISTED
Cidara Therapeutics
CDTX
$4.01M 0.6%
100,262
– –
TRVI icon
16
Trevi Therapeutics
TRVI
$2.49B
$3.33M 0.5%
1,263,408
-112,499
-8% -$364K
JNCE
17
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.35M 0.35%
334,965
– –
OBSV
18
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.08M 0.31%
999,364
– –
PVLA
19
Palvella Therapeutics
PVLA
$1.98B
$1.88M 0.28%
9,384
– –
PRVL
20
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-187,538
Closed -$1.91M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q4 2020 Portfolio in Review

As of Q4 2020, Omega Fund Management held 20 positions worth $667M, up 80% from $370M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Omega Fund Management deployed $192M of net new capital in Q4 2020, opening 4 new positions. Its largest new stake was Kronos Bio: 3,818,283 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Replimune Group, an estimated $11.3M trimmed.

  • Omega Fund Management's largest Q4 2020 buy was Kronos Bio: 3,818,283 shares worth $114M.
  • Omega Fund Management's biggest Q4 2020 reduction was Replimune Group, cutting an estimated $11.3M.
  • Omega Fund Management fully exited Prevail Therapeutics Inc. Common Stock in Q4 2020, selling an estimated $1.91M.
  • Omega Fund Management's ten largest holdings make up 91% of its $667M portfolio in Q4 2020.
  • Omega Fund Management opened 4 new positions and closed 1 in Q4 2020.
  • Omega Fund Management's portfolio value rose 80% quarter-over-quarter to $667M.

Based on Omega Fund Management's 13F filing for Q4 2020, filed 16 Feb 2021.